H.U. Group Research Institute

News Release

Company name: H.U. Group Research Institute, G.K.
Representative: Kazuya Omi, President

H.U. Group Research Institute to Establish an EViSTEP™-Based Platform for CSF-Derived Extracellular Vesicles with Eisai

Tokyo, Japan, March 18, 2026 --- H.U. Group Research Institute, G.K. (Head Office: Akiruno, Tokyo; hereinafter "HRI") announces that it has entered into a collaborative research agreement with Eisai Co., Ltd. (Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai") to advance next-generation biomarker discovery using cerebrospinal fluid (CSF)-derived extracellular vesicles (EVs).

Through this collaboration, HRI, a member of H.U. Group Holdings that drives technological innovation in the healthcare field under the concept of "No.1, Only One", and Eisai, a company dedicated to the development of innovative therapeutics with a primary focus on the central nervous system (CNS), aim to collaboratively create new value.

In this collaborative research project, the two companies will work to establish a high-performance isolation and analysis platform for CSF-derived EVs, achieving high recovery efficiency, high purity, and high throughput. EVs are lipid bilayer vesicles secreted by all cell types, including neurons, and have attracted considerable attention as analytical targets because the disease-related proteins and nucleic acids they carry reflect pathological conditions. CSF-derived EVs are expected to provide more CNS disease-specific information than blood-derived samples, enabling the generation of highly reliable data.

This collaborative research will leverage EViSTEP, a proprietary technology developed by HRI. EViSTEP is a selective isolation technology that uses high-affinity antibodies against EVs, achieving both high recovery rates and high purity, while enabling efficient EVs isolation in approximately 50 minutes. Furthermore, the use of the automated EVs isolation system "Autoevis™" allows for standardized operation and improved reproducibility, further enhancing the reliability of biomarker analyses.

Through this collaboration to establish optimized isolation and analysis technologies for CSF-derived EVs, the two companies aim to realize innovative diagnostic methods, prognostic prediction, and monitoring of therapeutic efficacy across disease areas, including neurological disorders. Through these efforts, the collaboration seeks to contribute to the advancement of personalized medicine and the establishment of new therapeutic strategies based on molecular-level understanding of disease pathology.

Contacts:

For media:

Public Relations Section, Public Relations/Sustainability Dept.
Phone: +81-3-6279-0884
E-mail: pr@hugp.com

For R&D:

Public Relations Section, R&D Planning Promotion Dept.
Phone: +81-50-2000-5697
E-mail: info-research@hugp.com